Edwards Lifesciences LLC

Edwards Lifesciences LLC, a for-profit limited liability company and self-certified small disadvantaged business, supplies transcatheter aortic valve replacement (TAVR) systems, transcatheter and surgical heart valves, annuloplasty systems, and related cardiovascular implants to the Department of Veterans Affairs as a prime contractor (100% of recent awards), with over 18,100 awards concentrated almost entirely within the VA healthcare system across multiple Veterans Integrated Service Networks.

Edwards Lifesciences LLC is a subsidiary of Edwards Lifesciences Corporation, a global cardiovascular medical device manufacturer. The subsidiary operates under NAICS 339113 (Surgical Appliance and Supplies Manufacturing) and PSC Medical and Surgical Instruments, Equipment, and Supplies, competing on a full-and-open basis without set-aside designation across all visible recent awards. Headquarters are at 1 Edwards Way, Irvine, California 92614.

The company's customer concentration is extreme and single-agency: the top five Veterans Integrated Service Networks by award count account for 37% of all awards and represent the entirety of significant federal business. VISN 21 (VA Palo Alto Health Care System) leads by potential value with $58.9 million across 1,197 awards, followed by VISN 8 (Tampa) with 2,019 awards and $50.5 million, and VISN 23 (Minneapolis) with 1,361 awards and $35.4 million. The top five VISNs collectively represent 47% of combined potential value across all 6,704 awards. All other federal agencies—Defense Health Agency, other service networks, and civilian departments—account for less than 3% of activity.

Edwards Lifesciences holds two named indefinite delivery contracts with the VA. The primary IDC is a $6.5 million single-award five-year consignment contract with VISN 21 (effective January 1, 2026 through December 31, 2030) for surgical implant services at VA Palo Alto Health Care System, employing a consignment model that allows the medical center to maintain optimized inventory of specialized cardiac devices and procure on an as-needed basis. A second $1 (placeholder-ceiling) single-award five-year IDC with VISN 12 covering structural heart valves and surgical implants on consignment through March 31, 2031 similarly operates a consignment structure for the William S. Middleton VA Hospital in Madison, Wisconsin. Both contracts were awarded as sole-source procurements under 41 U.S.C. 3304(a)(5) and 38 U.S.C. 8123, with Edwards Lifesciences determined to be the sole manufacturer capable of meeting brand-name and product-specific requirements. Individual task orders under these IDVs and standalone purchase orders typically range from $16,000 to $204,000, with representative 2026 awards including a $374,000 delivery order from VISN 17 for SAPIEN 3 RESILIA heart valves (May 31, 2030 completion), a $204,000 purchase order from VISN 21 for prosthetics and heart implants (May 29, 2026), and a $402,000 purchase order from VISN 7 for a hemodynamic monitoring system—HemoSphere Alta Cardiac Bundle (May 29, 2026). More typical transaction sizes run $32,500 to $68,000 per order.

Recent activity shows substantial volume. Awards per year over the past five years: 2022: 644, 2023: 735, 2024: 775, 2025: 757, and 2026: 276 (through mid-July, a partial-year figure). Combined potential value across all 18,132 awards stands at $434.4 million; combined dollars obligated represent $304.5 million (70% of potential value), indicating substantial historical payment and performance. Within the next twenty-four months, 142 awards with ultimate completion dates carry a combined potential value of $6.9 million—a modest recompete cliff relative to the vendor's total footprint, reflecting the consignment model's long-term stability through 2030 and 2031.

Top named parent vehicles are all VA IDCs and blanket purchase agreements: Indefinite Delivery Contract VA25514D0003 (210 task orders, $2.4 million), Indefinite Delivery Contract N6264514D5001 (87 task orders, $735 thousand), Basic Ordering Agreement VA25816A0019 (81 task orders, $739 thousand), Indefinite Delivery Contract VA25114D0137 (80 task orders, $770 thousand), and Blanket Purchase Agreement VA26116A0015 (51 task orders, $599 thousand). These vehicles are exclusively internal VA procurement structures with no indication of broader government-wide acquisition contract (GWAC) or GSA Schedule positioning.

Edwards Lifesciences LLC maintains one visible subcontract relationship: a sub-award to MEI Mail Services Inc. dated January 3, 2024, related to a research project on ferric iron-containing heme B complex and sulfane sulfur-linked dithiocarbamate as potential medical countermeasures. This sub-engagement is minimal relative to the vendor's prime footprint and does not reflect operational teaming.

Award data reflects Edwards Lifesciences' role as a sole-source medical device supplier to the VA's cardiac surgical programs. The vendor competes exclusively on full-and-open basis with no set-aside designations across all recent federal activity. Corporate structure identifies Edwards Lifesciences Corporation as parent and Enablecv, Inc. as a subsidiary of the parent (not operated by Edwards Lifesciences LLC). The company's federal profile is narrow and specialized—transcatheter heart valves, surgical implants, and critical care monitoring devices for the VA healthcare delivery system—with no meaningful diversification across civilian agencies, DoD prime work, or commercial markets visible in this federal contracting footprint.